Can a Macrophage-Targeting drug supercharge CAR-T therapy?
NCT ID NCT07638982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer more effectively. The study enrolls adults with certain aggressive lymphomas who are eligible for CAR-T therapy and aims to find the safest and most effective dose of axatilimab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axatilimab
What this could lead to
If successful, this combination could improve the effectiveness of CAR-T therapy for people with hard-to-treat lymphomas.
What could go wrong
This is an early-phase trial with a small number of participants. The drug may not improve outcomes and could cause additional side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northside Hospital
Atlanta, Georgia, 30342, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••